Date: 2015-08-11
Type of information: Nomination
Compound:
Company: Crispr Therapeutics (Switzerland - UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 11, 2015, CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, announced the expansion of the leadership team with the appointments of Samarth Kulkarni, Ph.D., as Chief Business Officer and Michael Bruce, Ph.D., as Senior Vice President, Program Portfolio and Alliance Management. Dr. Kulkarni joins CRISPR Therapeutics from McKinsey and Company where he was a Partner and had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, Dr. Kulkarni led initiatives in cutting edge areas such as personalized medicine and immunotherapy, where he co-authored several publications. He has a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, Dr. Kulkarni conducted research in the delivery of biological drugs and in the field of molecular diagnostics, which has been published in several leading journals. Dr. Bruce joins the team from Pfizer where he held positions of increasing responsibility over the last five years in the program, portfolio and alliance management functions. Most recently, he held the position of Vice President of Development Management and Business Operations for Worldwide Research & Development where he was responsible for the program management of all early stage (Ph 0-2) development programs in multiple therapeutic areas and modalities. He was also responsible for clinical trial business operations and alliance management, which was charged with operationalizing the portfolio of investments for all early clinical trials. Prior to Pfizer, Dr. Bruce served in roles of increasing responsibility in Oncology Project Management at Wyeth, including leading the development of bosutinib (Bosulif) from preclinical phase to submission. Dr. Bruce began his career as a scientist at Cambridge Discovery Chemistry, which was acquired by Millennium Pharmaceuticals. Dr. Bruce received his B.A. in chemistry from Williams College and Ph.D. in organic chemistry from Stanford University.
Financial terms:
Latest news:
